UsAgainstAlzheimers recently put out an email with great news!  Biogen is submitting an experimental Alzheimer’s drug (Aducanumab) to the Food and Drug Administration that has reduced clinical decline in patients with early Alzheimer’s disease across multiple areas.

This is an important first step that can help get a drug that treats Alzheimer’s closer to the people living with the disease. The Food and Drug Administration must approve this drug quickly once it is submitted so Biogen can start administering clinical trials to people living with Alzheimer’s. This is great news and gives hope that more cures are coming.

CLICK HERE to urge the FDA to conduct its review of this new Alzheimer’s drug as expeditiously as possible when the application is submitted so Biogen can start administering Aducanumab to people living with Alzheimer’s in clinical trials.

Share the knowledge...Share on Facebook
Tweet about this on Twitter
Share on LinkedIn
Pin on Pinterest
Share →

Leave a Reply

Your email address will not be published. Required fields are marked *